Amarin Co. plc (NASDAQ:AMRN) was the recipient of a significant growth in short interest in February. As of February 28th, there was short interest totalling 17,514,524 shares, a growth of 13.6% from the February 15th total of 15,412,976 shares. Based on an average daily volume of 10,037,142 shares, the short-interest ratio is presently 1.7 days. Approximately 6.1% of the company’s stock are short sold.

A number of research analysts recently weighed in on the stock. BidaskClub upgraded shares of Amarin from a “hold” rating to a “buy” rating in a report on Tuesday, November 27th. Cantor Fitzgerald set a $35.00 price objective on shares of Amarin and gave the company a “buy” rating in a report on Friday, December 28th. Citigroup dropped their price objective on shares of Amarin to $20.00 in a report on Tuesday, January 8th. Zacks Investment Research upgraded shares of Amarin from a “sell” rating to a “hold” rating in a report on Wednesday, January 23rd. Finally, SunTrust Banks restated a “buy” rating on shares of Amarin in a report on Monday, January 7th. Two research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $33.20.

NASDAQ AMRN opened at $20.46 on Thursday. Amarin has a 52 week low of $2.35 and a 52 week high of $23.33. The company has a market cap of $6.88 billion, a price-to-earnings ratio of -52.46 and a beta of 1.16.

Amarin (NASDAQ:AMRN) last posted its quarterly earnings results on Wednesday, February 27th. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.03). The business had revenue of $77.30 million for the quarter, compared to the consensus estimate of $73.87 million. During the same period in the previous year, the business earned ($0.08) EPS. The firm’s quarterly revenue was up 43.4% compared to the same quarter last year. Equities analysts forecast that Amarin will post -0.17 earnings per share for the current fiscal year.

In related news, General Counsel Joseph T. Kennedy sold 1,040,194 shares of Amarin stock in a transaction that occurred on Thursday, January 24th. The shares were sold at an average price of $17.77, for a total value of $18,484,247.38. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Michael Wayne Kalb sold 200,000 shares of Amarin stock in a transaction that occurred on Wednesday, January 9th. The shares were sold at an average price of $15.26, for a total transaction of $3,052,000.00. The disclosure for this sale can be found here. Insiders sold 2,841,072 shares of company stock valued at $49,748,088 in the last 90 days. Company insiders own 4.08% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the business. BlackRock Inc. grew its holdings in Amarin by 0.3% during the 3rd quarter. BlackRock Inc. now owns 3,403,454 shares of the biopharmaceutical company’s stock worth $55,374,000 after acquiring an additional 11,024 shares in the last quarter. Marshall Wace North America L.P. grew its holdings in Amarin by 175.9% during the 3rd quarter. Marshall Wace North America L.P. now owns 605,553 shares of the biopharmaceutical company’s stock worth $9,852,000 after acquiring an additional 386,032 shares in the last quarter. Claraphi Advisory Network LLC grew its holdings in Amarin by 5.8% during the 3rd quarter. Claraphi Advisory Network LLC now owns 55,521 shares of the biopharmaceutical company’s stock worth $903,000 after acquiring an additional 3,030 shares in the last quarter. Baker BROS. Advisors LP grew its holdings in Amarin by 50.3% during the 3rd quarter. Baker BROS. Advisors LP now owns 34,069,509 shares of the biopharmaceutical company’s stock worth $554,311,000 after acquiring an additional 11,400,000 shares in the last quarter. Finally, Credit Suisse AG acquired a new position in shares of Amarin in the 3rd quarter valued at $198,000. Institutional investors own 43.43% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Amarin Co. plc (AMRN) Short Interest Update” was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another domain, it was stolen and republished in violation of United States & international copyright & trademark laws. The correct version of this story can be accessed at https://www.thecerbatgem.com/2019/03/14/amarin-co-plc-amrn-short-interest-update.html.

Amarin Company Profile

Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product is Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.

Further Reading: What are the components of an earnings report?

Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.